Diamonte, Claudia

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Adusumilli, P. S., Zauderer, M. G., Rivière, I., Solomon, S. B., Rusch, V. W., O'Cearbhaill, R. E., Zhu, A., Cheema, W., Chintala, N. K., Halton, E., et al. (2021) · Cancer Discovery

CAR-T cell therapy researchCancer Immunotherapy and Biomarkers

Cited by 605

GPRC5D-Targeted CAR T Cells for Myeloma

Mailankody, S., Devlin, S. M., Landa, J., Nath, K., Diamonte, C., Carstens, E. J., Russo, D., Auclair, R., Fitzgerald, L., Cadzin, B., et al. (2022) · New England Journal of Medicine

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 411

Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma

Mailankody, S., Diamonte, C., Fitzgerald, L., Kane, P., Wang, X., Sikder, D. S., Senechal, B., Bermudez, V. P., Frias, D., Morgan, J., et al. (2021) · Blood

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 30